Apricus Biosciences Confirms Clinical Strategy for Novel Treatment for Symptomatic Secondary Hypogonadism Fispemifene

By: via Benzinga
Apricus Biosciences, Inc. (Nasdaq: APRI) today reaffirmed its regulatory and clinical strategy for the development of fispemifene in ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.